Phase 3 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women between 18 and 80 years old
- People who have had surgery for early-stage breast cancer where the cancer has spread to 1–3 nearby lymph nodes, the tumour is classified as T1 or T2 (relatively small), and lab testing has confirmed the cancer is hormone receptor-positive (ER+) and HER2-negative
- People whose cancer tests show that at least 50% of cancer cells are ER-positive (a specific hormone receptor measurement)
- People who are generally well enough to carry out light daily activities, with little or no limitation (confirm with trial site on how this is assessed)
- People whose blood, liver, and kidney test results fall within acceptable ranges — including healthy levels of red blood cells, white blood cells, and platelets, as well as normal liver enzyme and kidney function levels (confirm with trial site for exact values)
- People who have given their written agreement to take part and are willing to attend follow-up appointments
Who may not be able to join:
- People who received chemotherapy, targeted therapy, radiation, or hormone therapy before their surgery (neoadjuvant therapy)
- People who have cancer in both breasts
- People with a history of another cancer, unless it was a certain type of very early skin cancer (basal cell carcinoma) or early cervical cell changes (cervical carcinoma in situ) that were fully treated
- People whose breast cancer has spread to other parts of the body (Stage 4 or metastatic)
- People whose tumour is classified as T3 or larger (a larger tumour size category)
- People who are pregnant, breastfeeding, or of childbearing age and unable to use effective contraception during the trial
- People who are currently taking part in another clinical trial at the same time
- People with serious heart, lung, liver, or kidney problems — including reduced heart pumping function, a recent heart attack or stroke, uncontrolled high blood pressure, poorly controlled diabetes, or severe infection
- People whom the trial doctors consider unsuitable for the study for other medical reasons
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zhimin Shao, MD, PhD, Fudan University
Phone: +86-021-64175590
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Invasive disease free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.